05473nam 2200673 a 450 991045182170332120200520144314.01-280-66895-497866136458831-84816-450-5(CKB)2550000000101716(EBL)919104(OCoLC)794328399(SSID)ssj0000657469(PQKBManifestationID)12277381(PQKBTitleCode)TC0000657469(PQKBWorkID)10674717(PQKB)10002415(MiAaPQ)EBC919104(WSP)00002660(Au-PeEL)EBL919104(CaPaEBR)ebr10563562(CaONFJC)MIL364588(EXLCZ)99255000000010171620120608d2012 uy 0engur|n|---|||||txtccrMolecular exploitation of apoptosis pathways in prostate cancer[electronic resource] /Natasha KyprianouLondon Imperial College Press20121 online resource (230 p.)Molecular medicine and medicinal chemistry ;v. 5Description based upon print version of record.1-84816-449-1 Includes bibliographical references and index.Contents; Preface; Chapter 1 Introduction: Prostate Cancer; Chapter 2 The Prostate Gland Dynamics; Chapter 3 Apoptosis Pathways Signaling Execution of Cancer Cells; 3.1 Cell Choices of Life and Death; 3.1.1 "Classic" apoptosis; 3.1.2 Anoikis; 3.2 Caspases: The Apoptosis Executioners in a Therapeutic Setting; 3.3 The Mitochondrion: A Convenient Cell-Killing Platform; 3.4 Cell Surface Death Receptors and the FAS Ligand; 3.5 Meet the BCL-2 Family: Governors of Cell Survival and Death; 3.6 The Transcriptional Controllers; 3.7 The p53 Tumor Suppressor3.8 PTEN/PI3K/AKT: The Downstream Intracellular Players3.9 The Antagonists of Death: Inhibitors of Apoptosis Proteins (IAPs); 3.10 Apoptosis Signaling in the Endoplasmic Reticulum: A Death Platform for Stress; 3.11 The Tumor Microenvironment: Extracellular Forces Control Intracellular Death Outcomes; 3.11.1 Role of hypoxia; 3.11.2 The key growth factors; 3.11.3 Inflammation; Chapter 4 Androgen Receptor-Mediated Apoptosis: Significance in Development of Castration-Resistant Prostate Cancer; 4.1 The Androgen Receptor (AR); 4.2 Androgen Ablation: The Glory and the Failures4.3 AR Status in Castration-Resistant Prostate Cancer4.4 AR Interactions with Growth Factor Signaling Leads to Apoptosis; 4.4.1 AR connects with EGF; 4.4.2 AR and IGF interactions; 4.4.3 AR and TGF-β: partners in life and death (of the cell); 4.4.4 AR and FGF interactions; 4.4.5 AR and VEGF: Vascular exchanges for the "road"; 4.4.6 AR and growth factor interplay in the stroma; Chapter 5 Anoikis in Prostate Cancer Metastasis; 5.1 Anoikis Interrupted: Survival of the Homeless (Cells); 5.2 The Integrin Connection; 5.3 Impairing the Route to Angiogenesis; 5.3.1 Doxazosin; 5.3.2 Suramin5.3.3 Thalidomide5.3.4 Bevacizumab; 5.3.5 SU5416; 5.4 Anoikis and the Tumor Microenvironment: No "Resting" in the Stroma; 5.5 Signaling the "Homeless" State: Intracellular Anoikis Effectors; 5.6 Significance of Apoptosis in Cytoskeleton and Microtubule Targeting; 5.7 Autophagy: The Cellular Benefits of Starving to Death; Chapter 6 Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Metastasis; Chapter 7 Novel Molecular Therapeutics for Targeting Castration-Resistant Prostate Cancer; 7.1 Therapeutic Targeting of TGF-β Signaling7.2 Exploitation of Quinazolines: Lifting Anoikis Resistance to Impair Metastasis7.3 Receptor Tyrosine Kinase Targeting; 7.4 Histone Deacetylase Inhibitors (HDACs): Therapeutic Inhibitors; 7.5 Selective Death Action by Cancer-Specific PAR-4 in Prostate Tumors; 7.6 Death Synergy Between Proteosome and Death Receptor Leads to Tumor Regression; 7.7 The SERCA Pump as a Therapeutic Target; 7.8 Endothelin-Receptor Antagonists; 7.9 The Power of Sex Steroid Targeting; Chapter 8 Apoptotic-Based Molecular Markers of Therapeutic Response; Chapter 9 Role of Apoptosis in Prostate Cancer Prevention9.1 Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)This book focuses on the functional significance of targeting apoptosis for the treatment of prostate cancer. New concepts on the challenges relating to the development of resistance by androgen-independent tumors are introduced, in terms of the contribution of anoikis and cross-talk of androgens with key growth factor signaling pathways. This volume also provides insightful discussion on the exploitation of the apoptotic and angiogenic synergism towards complete eradication of prostate tumors. Last but not least, it includes reflections on the drug development challenge based on the analysis Molecular medicine and medicinal chemistry ;v. 5.ApoptosisProstateCancerTreatmentElectronic books.Apoptosis.ProstateCancerTreatment.616.99463Kyprianou Natasha885817MiAaPQMiAaPQMiAaPQBOOK9910451821703321Molecular exploitation of apoptosis pathways in prostate cancer1977920UNINA01316nam2 22003253i 450 PUV018411120231121125610.0IT1955 5555 20030522d1955 ||||0itac50 baitaitz01i xxxe z01n10: 1854 continuazioneC. Benso di Cavoura cura di Adolfo Omodeo e Luigi RussoFirenzeLa nuova Italiastampa 1955628 p.22 cm.001PUV01840942001 Discorsi parlamentariC. Benso di Cavour10Russo, Luigi <1892-1961>CFIV003748Omodeo, AdolfoRAVV027852ITIT-0120030522IT-RM028 IT-RM0289 IT-RM0290 IT-FR0017 Biblioteca Universitaria AlessandrinaRM028 Biblioteca Statale A. BaldiniRM0289 BIBLIOTECA ANGELICARM0290 Biblioteca umanistica Giorgio ApreaFR0017 NPUV0184111Biblioteca umanistica Giorgio Aprea 52MAG 2/848.10 52MAG0000091475 VMB A4 A 2019120620191206 01 04 06 5210: 1854 continuazione3613203UNICAS